Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?

Background: Circulating tumor cell (CTC) counting may be a useful non-invasive biomarker that helps patients choose first-line treatment options. Nevertheless, the cost of CTC inspection may impose an economic burden on patients, necessitating the simultaneous consideration of both its clinical effe...

全面介绍

书目详细资料

Principais autores:	Huiting Lin, Wenhua Wu, Xiaoya Lou, Yiming Wang, Hong Sun, Jiaqin Cai, Suyan Liu, Xiaoxia Wei
格式:	Artigo
语言:	Inglês
出版:	Elsevier 2024-04-01
丛编:	Breast
主题:	Circulating tumor cell Cost-effectiveness analysis Breast cancer Markov model
在线阅读:	http://www.sciencedirect.com/science/article/pii/S0960977624000110
标签:	添加标签 没有标签, 成为第一个标记此记录!